{"id":974599,"date":"2026-06-23T07:30:09","date_gmt":"2026-06-23T11:30:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/"},"modified":"2026-06-23T07:30:09","modified_gmt":"2026-06-23T11:30:09","slug":"cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/","title":{"rendered":"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n TORONTO<\/span>, June 23, 2026<\/span> \/PRNewswire\/ – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the “AGM”) will be webcast on June 24, 2026, at 4:30 p.m. EDT.<\/p>\n

\n

\n
\n \"Cardiol
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Cardiol Therapeutics’ 2026 AGM<\/b>\n <\/p>\n

When: June 24, 2026, at 4:30 p.m. EDT
Where: Virtual meeting only via live webcast online at: meetings.lumiconnect.com\/400-405-294-535<\/a><\/p>\n

Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com\/investors\/events-presentations\/<\/a>.<\/p>\n

\n About Cardiol Therapeutics<\/b>\n <\/p>\n

Cardiol Therapeutics Inc. (NASDAQ: CRDL<\/b>) (TSX: CRDL<\/b>) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx\u2122, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.<\/p>\n

The MAVERIC Program is evaluating CardiolRx\u2122<\/sup> for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx\u2122 for the treatment of pericarditis, including recurrent pericarditis.<\/p>\n

The ARCHER Program also studied CardiolRx\u2122<\/sup> in acute myocarditis\u2014an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx\u2122<\/sup> in this patient population.<\/p>\n

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure\u2014a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.<\/p>\n

For more information about Cardiol Therapeutics, please visit cardiolrx.com.<\/p>\n

\n Cautionary statement regarding forward-looking information:
<\/b>
\n This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are “forward-looking information”. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx\u2122<\/sup>; the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, including through the initiation of a Phase I clinical program; and the Company’s ability to address its strategic priorities. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.<\/i>\n <\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-pm-edt-302807049.html<\/a><\/p>\n

SOURCE Cardiol Therapeutics Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire TORONTO, June 23, 2026 \/PRNewswire\/ – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the “AGM”) will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics’ 2026 AGM When: June 24, 2026, at 4:30 p.m. EDTWhere: Virtual meeting only via live webcast online at: meetings.lumiconnect.com\/400-405-294-535 Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com\/investors\/events-presentations\/. About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory … <\/p>\n

Continue reading “Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-974599","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TORONTO, June 23, 2026 \/PRNewswire\/ – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the “AGM”) will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics’ 2026 AGM When: June 24, 2026, at 4:30 p.m. EDTWhere: Virtual meeting only via live webcast online at: meetings.lumiconnect.com\/400-405-294-535 Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com\/investors\/events-presentations\/. About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory … Continue reading "Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T11:30:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2998611\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT\",\"datePublished\":\"2026-06-23T11:30:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/\"},\"wordCount\":781,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2998611\\\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/\",\"name\":\"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2998611\\\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg\",\"datePublished\":\"2026-06-23T11:30:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2998611\\\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2998611\\\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/","og_locale":"en_US","og_type":"article","og_title":"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Market Newsdesk","og_description":"PR Newswire TORONTO, June 23, 2026 \/PRNewswire\/ – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, announces that the Company’s virtual Annual General Meeting of Shareholders (the “AGM”) will be webcast on June 24, 2026, at 4:30 p.m. EDT. Cardiol Therapeutics’ 2026 AGM When: June 24, 2026, at 4:30 p.m. EDTWhere: Virtual meeting only via live webcast online at: meetings.lumiconnect.com\/400-405-294-535 Additional information about the AGM, including details on how to participate and vote, is available on the Company’s website at cardiolrx.com\/investors\/events-presentations\/. About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory … Continue reading \"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-23T11:30:09+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2998611\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT","datePublished":"2026-06-23T11:30:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/"},"wordCount":781,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2998611\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/","name":"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2998611\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg","datePublished":"2026-06-23T11:30:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2998611\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2998611\/Cardiol_Therapeutics_Inc__Cardiol_Therapeutics_to_Webcast_Virtua.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiol-therapeutics-to-webcast-virtual-annual-general-meeting-of-shareholders-on-june-24th-at-430-p-m-edt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=974599"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/974599\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=974599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=974599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=974599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}